Dozens of Clinical Trial Results Demonstrate 'Wonder Drug' Ivermectin is Effective Against COVID-19
Scientists call it a safe and versatile 'wonder drug'; too often, journalists denigrate it as merely a horse dewormer. What might explain the discrepancy?
‘There are already dozens of clinical trial results that have been accumulated to date that demonstrate that ivermectin is effective against COVID-19.’
Yagisawa, M., Foster, P. J., Hanaki, H., & Ōmura, S. (2021). Global trends in clinical studies of ivermectin in COVID-19. The Japanese Journal of Antibiotics, 74, 1.
In a statement to the World Health Organisation, Professor Yagisawa referenced ‘105 studies of ivermectin associated with the coronavirus across 32 nations have been registered, of which 24 have been completed and published’. On this basis, Yagisawa asserts that ivermectin can be used to prevent and treat (both early and late-stage) COVID-19. (You read more about this here, and listen to his statement here.)
In their 2021 paper, Yagisawa and colleagues (including Nobel-prize winner Satoshi Omura) state that ‘A meta-analysis of 14,906 patients in 42 clinical trials [have] shown sufficient efficacy of ivermectin, with a 1 in 4 trillion chance of the conclusion being a mistake’. And further that 21 of these trials, employing 2,869 patients, were randomised controlled trials, considered the most reliable evidence of the effectiveness of an intervention. This is followed by entreating regulators to explain why studies of this magnitude are supposedly inadequate, particularly in light of the ‘hundreds of thousands of people worldwide being infected and thousands [who] continue to die every day’.
Scientists refer to ivermectin as a 'wonder drug' worthy of sharing a pedestal with penicillin and aspirin; they speak of its ‘astonishing’ safety and versatility, of the ‘new and promising properties and uses for ivermectin and other avermectin derivatives [that] are continuing to be found’ in human medicine (see Ivermectin, ‘Wonder drug’ from Japan: the human use perspective).
In sharp contrast, propaganda peddlers denigrate ivermectin as a ‘horse dewormer’ at every turn and disparage it as a ‘cheap drug’ or a ‘decades-old parasite drug’. The word cheap has pejorative connotations, unlike ‘inexpensive’. Even ‘decades-old’ is the truth in the form of a slight, as though only a new drug could have the properties necessary to treat a new strain of coronavirus. When ivermectin is mentioned, it is typically only to caution people against resorting to self-medicating with products formulated for horses.
Yagisawa and colleagues (2021) offer compelling evidence that ivermectin is an effective, safe and inexpensive drug with utility in preventing and treating COVID-19. Highly profitable vaccines with potentially many as-yet-unknown side effects can only be rolled out on an emergency basis if there is no treatment. Could this be why ivermectin is seemingly being suppressed by regulatory bodies that are partially funded by the industry?
‘If we use ivermectin for prophylaxis, pharmaceutical companies will lose the market of vaccine throughout the world,’ says Yasigawa while comparing the price of ivermectin to Pfizer, one of the three vaccines approved for use in Japan.
I’m inclined to agree with this theory.
Ivermectin in a nutshell:
"Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified." —Link to study
‘Ivermectin distribution campaigns’ refer to, for example, Goa, India where it has been in use since May 2021. On that note, the Indian Bar Association are taking WHO to task for costing lives in the State of Tamil Nadu on the say-so of Merck. This pharmaceutical company was working on novel (non-patent expired and lucrative) therapeutics at the time, so their lack of objectivity does not surprise me.
Thanks for reading. If you enjoyed this article, all I ask is that you share it so I can increase my readership.